Bayer and Ardea in Cancer Drug Deal

By Taskin Ahmed

Pharma Deals Review: Vol 2009 Issue 4 (Table of Contents)

Published: 29 Apr-2009

DOI: 10.3833/pdr.v2009.i4.1101     ISSN: 1756-7874

Section: Licensing

Fulltext:

Abstract

Bayer has entered into a global agreement with San Francisco-based Ardea Biosciences focused on the development of mitogen-activated ERK kinase inhibitors for the treatment of solid tumours...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details